GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (NAS:IOVA) » Definitions » Total Inventories

Iovance Biotherapeutics (Iovance Biotherapeutics) Total Inventories : $10.37 Mil (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Iovance Biotherapeutics Total Inventories?

Iovance Biotherapeutics's total inventories for the quarter that ended in Dec. 2023 was $10.37 Mil. Iovance Biotherapeutics's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $9.78 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Iovance Biotherapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $0.35.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Iovance Biotherapeutics's Days Inventory for the three months ended in Dec. 2023 was 204.52.

Inventory Turnover measures how fast the company turns over its inventory within a year. Iovance Biotherapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.45.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Iovance Biotherapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 20.30.


Iovance Biotherapeutics Total Inventories Historical Data

The historical data trend for Iovance Biotherapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iovance Biotherapeutics Total Inventories Chart

Iovance Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 10.37

Iovance Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 9.72 9.20 10.37

Iovance Biotherapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Iovance Biotherapeutics  (NAS:IOVA) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Iovance Biotherapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(279.867+0.75 * 0.151+0.5 * 10.372-195.738
-0.003-0)/256.136
=0.35

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Iovance Biotherapeutics's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=9.7835/4.365*365 / 4
=204.52

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Iovance Biotherapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=4.365 / 9.7835
=0.45

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Iovance Biotherapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=9.7835 / 0.482
=20.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Iovance Biotherapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Iovance Biotherapeutics (Iovance Biotherapeutics) Business Description

Traded in Other Exchanges
Address
825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Executives
Merrill A Mcpeak director PO BOX 500 (M/S 55-985), 14200 SW KARL BRAUN DRIVE, BEAVERTON OR 97077-0001
Wayne P. Rothbaum director C/O QUOGUE CAPITAL LLC, 1285 AVENUE OF THE AMERICAS, 35TH FLOOR, NEW YORK NY 10019
Wendy L Yarno director
Frederick G Vogt officer: General Counsel 2120 HEMLOCK RD., WEST NORRITON PA 19403
Iain D. Dukes director 112 W. 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Wendy L Dixon director
Ryan D Maynard director RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Michael Weiser director C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Igor Bilinsky officer: Chief Operating Officer C/O VICAL INCORPORATED, 10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jean-marc Bellemin officer: Chief Financial Officer C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Michael Swartzburg officer: VP, Finance C/O AVALANCHE BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Athena Countouriotis director C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Finckenstein Friedrich Graf officer: Chief Medical Officer 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Timothy E Morris officer: Chief Financial Officer ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Maria Fardis director, officer: President and CEO C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085